# Study to Evaluate the Safety and Efficacy of PAZ320 in Patients With Type 2 Diabetes

> **NCT02060916** · PHASE2 · COMPLETED · sponsor: **Boston Therapeutics** · enrollment: 24 (actual)

## Conditions studied

- Type 2 Diabetes Treated With Insulin

## Interventions

- **DRUG:** PAZ320

## Key facts

- **NCT ID:** NCT02060916
- **Lead sponsor:** Boston Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-03
- **Primary completion:** 2011-08
- **Final completion:** 2011-08
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2014-02-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02060916

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02060916, "Study to Evaluate the Safety and Efficacy of PAZ320 in Patients With Type 2 Diabetes". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT02060916. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*